




Instance: composition-en-e8b67f07b418969c3e83d3aef06331ab
InstanceOf: CompositionUvEpi
Title: "Composition for qarziba Package Leaflet"
Description:  "Composition for qarziba Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpc4c16a48ac49597099fd0a00a176f2b9)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - qarziba"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What Qarziba is and what it is used for </li>
<li>What you need to know before you use Qarziba </li>
<li>How to use Qarziba </li>
<li>Possible side effects </li>
<li>How to store Qarziba </li>
<li>Contents of the pack and other information </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What qarziba is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What qarziba is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Qarziba contains dinutuximab beta, which belongs to a group of medicines called  monoclonal 
antibodies . These are proteins, which specifically recognise and bind to other unique proteins in the 
body. Dinutuximab beta binds to the molecule known as disialoganglioside 2 (GD2), which is present 
on cancer cells, and this activates the body s immune system, causing it to attack the cancer cells. </p>
<p>Qarziba is used to treat neuroblastoma that has a high risk of coming back after a series of 
treatments, which include a stem cell transplantation for rebuilding the immune system. It is also used 
to treat neuroblastoma that has come back (relapsed) or could not be completely treated with previous 
therapies. </p>
<p>Prior to the treatment of relapsed neuroblastoma, your treating physician will stabilise any actively 
progressing disease by other suitable measures. </p>
<p>Your doctor will further decide whether the co-administration of a second medicine, interleukin-2, is 
necessary for the treatment of your cancer. </p>
<p>Neuroblastoma is a type of cancer that grows from abnormal nerve cells in the body, in particular in 
the glands above the kidneys. It is one of the most common cancers in infancy. </p>
<p>It is used for patients aged 12 months and above. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take qarziba"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take qarziba"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not use Qarziba if you </p>
<ul>
<li>are allergic to dinutuximab beta or any of the other ingredients of this medicine (listed in 
section 6) </li>
<li>have acute grade 3 or 4, or extensive long-lasting graft-versus-host disease 
This disease is a reaction in which cells of transplanted tissue attack cells of the recipient. </li>
</ul>
<p>Warnings and precautions </p>
<p>Before receiving Qarziba, you will have blood tests to check your liver, lung, renal and bone marrow 
functions. </p>
<p>You might notice the following when you first receive Qarziba and during the course of treatment: 
* pain 
Pain is one of the most common side effects of Qarziba. It usually occurs at the beginning of 
infusion. Therefore, your doctor will give you an appropriate pain treatment starting 3 days 
before and continuing during use of Qarziba. 
* allergic reactions or other infusion-related reactions 
Tell your doctor or nurse if you have any kind of reaction during or after the infusion, such as:</p>
<ul>
<li>fever, shivering and/or low blood pressure </li>
<li>difficulties in breathing </li>
<li>skin rash, hives 
You will receive appropriate treatment to prevent these reactions and be closely monitored for 
these symptoms during infusion of Qarziba. </li>
<li>leakage from small blood vessels (capillary leak syndrome) 
Leakage of blood components from small blood vessels may cause rapid swelling in arms, legs 
and other parts of the body. Rapid drop in blood pressure, light-headedness and breathing 
difficulties are further signs. </li>
<li>eye problems 
You may notice changes to your vision. </li>
<li>problems with your nerves 
You may notice numbness, tingling or burning in your hands, feet, legs or arms, reduced 
sensation or weakness with movement. </li>
<li>spinal cord and brain problems (central nervous system, CNS) 
Tell your doctor or nurse if you have any kind of CNS symptoms, such as: substantial 
prolonged neurological deficit without apparent reason such as muscle weakness or loss of 
muscle strength in the legs (or arms), or mobility problems or unusual sensations and numbness. 
Persistent or sudden onset of a headache, or progressive loss of memory and cognitive ability, 
subtle personality changes, inability to concentrate, lethargy, and progressive loss of 
consciousness. </li>
</ul>
<p>Tell your doctor immediately if you notice any of these problems. </p>
<p>Your doctor may decide to stop your treatment if you have any of the problems mentioned here.  In 
some cases your treatment may be able to start again after a break or at a slower rate, but sometimes it 
may need to be stopped completely. </p>
<p>Your doctor will do blood tests and may do eye tests while you are taking this medicine. </p>
<p>Children </p>
<p>This medicine should not be given to children under 12 months because there is insufficient 
experience in this age group. </p>
<p>Other medicines and Qarziba </p>
<p>Tell your doctor if you are using, have recently used or might use any other medicines. </p>
<p>Do not use medicines that suppress the immune system from 2 weeks before the first dose of 
Qarziba until 1 week after the last treatment course, unless prescribed by your doctor. Examples of 
medicines that suppress the immune system are corticosteroids used to reduce inflammation or prevent 
organ transplant rejection. </p>
<p>Avoid vaccinations during treatment with Qarziba and for 10 weeks afterwards.  </p>
<p>Pregnancy, breast-feeding and fertility </p>
<p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask 
your doctor for advice before taking this medicine.  </p>
<p>Talk to your doctor before you receive Qarziba if you are of childbearing age. It is recommended to 
use contraception for 6 months after discontinuation of treatment with Qarziba. You may only use 
Qarziba if your doctor assesses that benefits outweigh risks for a foetus. </p>
<p>Tell your doctor if you are breast-feeding. Do not breast-feed during treatment with Qarziba and for 
6 months after the last dose. It is not known if the medicine can pass into breast-milk. </p>
<p>Driving and using machines </p>
<p>Qarziba has several side effects that may affect your ability to drive and use machines. Do not perform 
these activities if your ability to concentrate and react is affected. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take qarziba"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take qarziba"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>A doctor experienced in the use of medicines to treat cancer will supervise your treatment. It will be 
given to you by a doctor or nurse while you are in hospital. It is given into one of your veins 
(intravenous infusion) usually by using special tubes (catheters) and a pump. During and after the 
infusion, you will be checked regularly for infusion-related side effects. </p>
<p>Qarziba will be given to you in five treatment courses of 35 days and the infusion will last 5 or 10 days 
in the beginning of each course. The recommended dose is 100 mg dinutuximab beta per square 
metre of body surface per treatment course. The doctor will calculate your body surface area from 
your height and weight. </p>
<p>If your doctor considers co-administration of interleukin-2, it will be given twice, by injection under 
the skin, each time for 5 consecutive days (before and during treatment with Qarziba). </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. </p>
<p>Tell your doctor or nurse immediately if you have any of the following: 
Very common (may affect more than 1 in 10 people): 
* rapid swelling of arms, legs and other body parts, rapid drop in blood pressure, light-headedness 
and breathing difficulties (capillary leak syndrome) 
* pain in the stomach, throat, chest, face, hands, feet, legs, arms, back, neck, joint, or muscles 
* allergic reactions and cytokine release syndrome with symptoms such as face or throat swelling, 
breathing difficulties, dizziness, hives, rapid or noticeable heartbeat, low blood pressure, hives, 
rash, fever, or nausea </p>
<p>Other side effects and their frequencies include: 
Very common (may affect more than 1 in 10 people): 
* fever, chills 
* vomiting, diarrhoea, constipation 
* inflammation of the mouth and lips (stomatitis) 
* cough 
* itching, rash 
* low blood pressure, increased heartbeat 
* oxygen deficiency 
* tissue swelling (in the face, lip, around the eye, in the lower limbs) 
* increased weight 
* infection, in particular infection associated with the catheter that delivers the medicine 
* headache 
* dilated pupils or abnormal pupil reactions 
* abnormal blood or urine tests (blood cells and other components, liver function, renal function) </p>
<p>Common (may affect up to 1 in 10 people): 
* life-threatening infection (sepsis) 
* fits 
* agitation, anxiety 
* nerve disorder in the arms and/or legs (with abnormal sensations or weakness), light-
headedness, trembling, muscle spasms 
* paralysis of eye muscles, blurred vision, light sensitivity, swelling in the retina 
* high blood pressure 
* cardiac failure, fluid around the heart 
* respiratory failure, fluid in the lungs 
* sudden constriction of the airways (bronchospasm, laryngospasm), rapid breathing 
* decreased appetite, nausea, abdominal distension, accumulation of fluid in the abdominal cavity 
* injection-site reactions, skin problems such as reddening, dry skin, eczema, excessive sweating, 
reaction to light 
* unable to pass urine or passing reduced urine volume 
* decreased weight, loss of fluids (dehydration) </p>
<p>Uncommon (may affect up to 1 in 100 people): 
* shock due to decreased body fluid volume 
* formation of blood clots in the small blood vessels (disseminated intravascular coagulation) 
* a type of allergy (serum sickness) with fever, rash, joint inflammation 
* a brain disorder characterised by headache, confusion, seizures and loss of vision (posterior 
reversible encephalopathy syndrome) 
* inflammation of the intestine, injury to the liver 
* kidney failure 
* a condition in which some of the small veins in the liver are obstructed (veno-occlusive disease) </p>
<p>Reporting of side effects 
If you get any side effects, talk to your doctor or nurse. This includes any possible side effects not 
listed in this leaflet. You can also report side effects directly via the national reporting system listed in 
Appendix V. By reporting side effects, you can help provide more information on the safety of this 
medicine. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store qarziba"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store qarziba"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children. </p>
<p>Do not use this medicine after the expiry date which is stated on the label and the carton after EXP. 
The expiry date refers to the last day of that month. </p>
<p>Store in a refrigerator (2  C   8  C). Keep the vial in the outer carton in order to protect from light. </p>
<p>Once opened, Qarziba is intended for immediate use. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Qarziba contains </p>
<ul>
<li>The active substance is dinutuximab beta. 
1 mL concentrate contains 4.5 mg dinutuximab beta. Each vial contains 20 mg dinutuximab 
beta in 4.5 mL. </li>
<li>The other ingredients are histidine, sucrose, polysorbate 20, water for injections, hydrochloric 
acid (for pH adjustment). </li>
</ul>
<p>What Qarziba looks like and contents of the pack </p>
<p>Qarziba is colourless to slightly yellow liquid, provided in a clear glass vial with a rubber stopper and 
aluminium seal. 
Each carton contains 1 vial. </p>
<ul>
<li>
<p>Marketing Authorisation Holder 
Recordati Netherlands B.V. 
Beechavenue 54, 
1119PW Schiphol-Rijk 
Netherlands </p>
</li>
<li>
<p>Manufacturer 
Millmount Healthcare Ltd 
Block 7, City North Business Campus 
Stamullen, Co. Meath 
K32 YD reland </p>
</li>
</ul>
<p>Patheon Italia S.P.A. 
Via Morolense, 
5   03013 Ferentino 
Italy </p>
<p>This leaflet was last revised in {MM/YYYY}. </p>
<p>Other sources of information </p>
<p>Detailed information on this medicine is available on the European Medicines Agency website: 
http://www.ema.europa.eu. There are also links to other websites about rare diseases and treatments. </p>
<hr />
<p>The following information is intended for healthcare professionals only: </p>
<p>Qarziba is restricted to hospital-use only and must be administered under the supervision of a 
physician experienced in the use of oncological therapies. It must be administered by a healthcare 
professional prepared to manage severe allergic reactions including anaphylaxis in an environment 
where full resuscitation services are immediately available. </p>
<p>Posology 
Treatment with dinutuximab beta consists of 5 consecutive courses, each course comprising 35 days. 
The individual dose is determined based on the body surface area and should be a total of 100 mg/m2 
per course. </p>
<p>Two modes of administration are possible: 
* a continuous infusion over the first 10 days of each course (a total of 240 hours) at the daily 
dose of 10 mg/m2 
* or five daily infusions of 20 mg/m2 administered over 8 hours, on the first 5 days of each course </p>
<p>If IL-2 is combined with dinutuximab beta, it should be given as subcutaneous injections for 
5 consecutive days twice during each course. First 5-day treatment should start 7 days prior to first 
dinutuximab beta infusion. Second 5-day treatment with IL-2 should start concurrently with 
dinutuximab beta infusion (days 1 to 5 of each course). IL-2 is administered as 6 106 IU/m2/day, 
resulting in an overall dose of 60 106 IU/m2/course. </p>
<p>Preparation of the infusion 
The solution for infusion must be prepared under aseptic conditions. The solution must not be exposed 
to direct sunlight or heat. </p>
<p>The patient-specific daily dose of Qarziba is calculated based on body surface area. Qarziba should be 
diluted aseptically to the patient-specific concentration/dose with sodium chloride 9 mg/mL (0.9%) 
solution for infusion, containing 1% human albumin (e.g. 5 mL of human albumin 20% per 100 mL 
sodium chloride solution). </p>
<ul>
<li>
<p>For continuous infusions, the solution for infusion can be prepared freshly on a daily basis, or 
sufficient for up to 5 days of continuous infusion. The daily dose is 10 mg/m2. The amount of 
solution to be infused per day (within a treatment course of 10 consecutive days) should be 
48 mL; with 240 mL for a 5-day dose. It is recommended to prepare 50 mL solution in a 50 mL 
syringe, or 250 mL in an infusion bag suitable for the employed infusion pump, i.e. an overfill 
of 2 mL (syringe) or 10 mL (infusion bag) to allow for dead volumes of the infusion systems. </p>
</li>
<li>
<p>For repeated daily infusions, the daily dose is 20 mg/m2 and the calculated dose should be 
diluted in 100 mL sodium chloride 9 mg/mL (0.9%) containing 1% human albumin. </p>
</li>
</ul>
<p>Administration of the infusion 
The solution for infusion should be administered via a peripheral or central intravenous line. Other 
intravenously co-administered agents should be delivered via a separate infusion line. The container 
should be inspected visually for particulates prior to administration. It is recommended that a 
0.22 micrometre in-line filter is used during infusion. </p>
<p>For continuous infusions, any medical device suitable for infusion at a rate of 2 mL per hour can be 
applied, e.g. syringe infusion pumps/infusors, electronic ambulatory infusion pumps. Note that 
elastomeric pumps are not considered suitable in combination with in-line filters. </p>
<p>Storage of the diluted solution 
Chemical and physical in-use stability has been demonstrated for up to 48 hours at 25  C (50 mL 
syringe) and for up to 7 days at 37  C (250 mL infusion bag), after cumulative storage in a refrigerator 
(2  C   8  C) for 72 hours. </p>
<p>From a microbiological point of view, the product should be used immediately. If not used 
immediately, in-use storage times and conditions prior to use are the responsibility of the user and 
would not normally be longer than 24 hours at 2 to 8  C, unless dilution has taken place in controlled 
and validated aseptic conditions. </p>
<p>Disposal 
Any unused medicinal product or waste material should be disposed of in accordance with local 
requirements. </p>         </div>"""      



Instance: composition-da-e8b67f07b418969c3e83d3aef06331ab
InstanceOf: CompositionUvEpi
Title: "Composition for qarziba Package Leaflet"
Description:  "Composition for qarziba Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpc4c16a48ac49597099fd0a00a176f2b9)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - qarziba"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen </p>
<ol>
<li>Virkning og anvendelse </li>
<li>Det skal du vide, før du begynder at få Qarziba </li>
<li>Sådan får du Qarziba </li>
<li>Bivirkninger </li>
<li>Opbevaring </li>
<li>Pakningsstørrelser og yderligere oplysninger </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What qarziba is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What qarziba is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Qarziba indeholder dinutuximab beta, der tilhører en gruppe lægemidler, der kaldes monoklonale 
antistoffer. Det er proteiner, der specifikt er i stand til at genkende og binde sig til andre unikke 
proteiner i kroppen. Dinutuximab beta binder til et molekyle, der kaldes disialogangliosid 2 (GD2), 
der findes på kræftceller, og dette aktiverer kroppens immunsystem til at angribe kræftceller. </p>
<p>Qarziba anvendes til at behandle neuroblastom, der har en høj risiko for at vende tilbage, efter en 
række behandlinger, der omfatter en stamcelletransplantation til genopbygning af immunsystemet. Det 
anvendes også til at behandle neuroblastom, der er vendt tilbage (relaps), eller som ikke kunne 
behandles fuldstændigt med de foregående behandlinger.  </p>
<p>Før behandling af relaps af neuroblastom vil din læge stabilisere alle andre aktive progressive 
sygdomme med andre egnede midler. </p>
<p>Din læge vil endvidere beslutte, om du samtidig skal have et andet lægemiddel, interleukin-2, til at 
behandle din cancer. </p>
<p>Neuroblastom er en type cancer, der vokser fra abnorme nerveceller i kroppen, og specielt i kirtler 
over nyrerne. Det er en af de mest almindelige kræftsygdomme hos børn. </p>
<p>Stoffet kan anvendes til patienter fra 12 måneder og opefter. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take qarziba"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take qarziba"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Få ikke Qarziba, hvis du </p>
<ul>
<li>
<p>er allergisk over for dinutuximab beta eller et af de øvrige indholdsstoffer i Qarziba (angivet i 
punkt 6) </p>
</li>
<li>
<p>har akut graft versus host-sygdom af grad 3 eller 4 eller massiv langvarig graft versus host-
sygdom 
Graft versus host-sygdom er en reaktion, hvor cellerne i det transplanterede væv angriber 
kroppens celler. </p>
</li>
</ul>
<p>Advarsler og forsigtighedsregler </p>
<p>Før du får Qarziba, vil du få taget blodprøver for at kontrollere, hvordan din lever, dine lunger og 
nyrer samt din knoglemarv fungerer. </p>
<p>Du vil måske bemærke følgende, når du får Qarziba og under behandlingen: </p>
<ul>
<li>
<p>Smerter 
Smerter er en af de hyppigste bivirkninger ved Qarziba. De starter normalt ved begyndelsen af 
infusionen. Derfor vil din læge give dig passende smertebehandling fra 3 dage før og under 
behandlingen med Qarziba. </p>
</li>
<li>
<p>Allergiske reaktioner og andre reaktioner på infusionen 
Fortæl din læge eller sundhedspersonalet, hvis du får en eller anden form for reaktion under 
eller efter infusionen, som f.eks.:</p>
</li>
<li>
<p>feber, kulderystelser og/eller lavt blodtryk (bliver svimmel) </p>
</li>
<li>besvær med at trække vejret </li>
<li>
<p>hududslæt, nældefeber. 
Du vil få passende behandling for at forebygge disse reaktioner og blive nøje overvåget for 
sådanne symptomer under infusionen af Qarziba. </p>
</li>
<li>
<p>Sivning fra små blodkar (kapillærlækage-syndrom) 
Sivning af blodceller fra små blodkar kan forårsage hurtig opsvulmning i arme, ben og andre 
steder i kroppen. Hurtigt fald i blodtrykket, svimmelhed og åndedrætsbesvær er yderligere tegn. </p>
</li>
<li>
<p>Øjenproblemer 
Du vil muligvis mærke ændringer i dit syn. </p>
</li>
<li>
<p>Nerveproblemer 
Du kan bemærke følelsesløshed, prikkende eller brændende fornemmelse i hænder, fødder, 
arme eller ben, og nedsat følsomhed eller svaghed i forbindelse med bevægelse. </p>
</li>
<li>
<p>Rygmarvs- og hjerneproblemer (centralnervesystemet, CNS) 
Tal med lægen eller sygeplejersken, hvis du har nogen form for CNS-symptomer, såsom: 
væsentlig langvarig neurologisk funktionsforstyrrelse uden en klar årsag, såsom muskelsvaghed 
eller tab af muskelstyrke i benene (eller armene), eller mobilitetsproblemer eller 
føleforstyrrelser og følelsesløshed. Vedvarende eller pludseligt opstået hovedpine eller 
fremadskridende tab af hukommelse og kognitiv funktionsevne, små personlighedsændringer, 
manglende koncentrationsevne, sløvhed og fremadskridende bevidsthedstab. </p>
</li>
</ul>
<p>Kontakt lægen med det samme, hvis du bemærker en eller flere af disse bivirkninger. </p>
<p>Lægen kan beslutte at stoppe din behandling, hvis du har nogen af ovennævnte problemer. I nogle 
tilfælde kan det være muligt at starte din behandling igen efter en afbrydelse eller ved en langsommere 
hastighed, men undertiden kan det være nødvendigt at stoppe behandlingen helt. </p>
<p>Din læge vil tage blodprøver og muligvis teste dine øjne, mens du tager dette lægemiddel. </p>
<p>Børn </p>
<p>Dette lægemiddel må ikke gives til børn under 12 måneder, da der er for få erfaringer hos denne 
aldersgruppe. </p>
<p>Brug af andre lægemidler sammen med Qarziba </p>
<p>Fortæl det altid til lægen, hvis du bruger andre lægemidler, for nylig har brugt andre lægemidler eller 
planlægger at bruge andre lægemidler. </p>
<p>Undgå at anvendelægemidler, der svækker immunsystemet, fra 2 uger før den første dosis af 
Qarziba og indtil 1 uge efter, den sidste behandlingsserie er afsluttet, medmindre din læge har 
ordineret det. Eksempler på lægemidler, der svækker immunsystemet, er kortikosteroider, der 
anvendes til at behandle inflammation (betændelseslignende reaktioner) og forebygge afstødning af et 
transplantat. </p>
<p>Undgå at blive vaccineret under behandlingen med Qarziba og i 10 uger efter, behandlinger er 
afsluttet. </p>
<p>Graviditet, amning og frugtbarhed </p>
<p>Hvis du er gravid eller ammer, har mistanke om, at du er gravid, eller planlægger at blive gravid, skal 
du spørge din læge til råds, før du får dette lægemiddel. </p>
<p>Tal med din læge, før du skal have Qarziba, hvis du er en kvinde i den fødedygtige alder. Det 
anbefales at anvende kontraception 6 måneder efter, at behandlingen med Qarziba er afsluttet. Du må 
kun få Qarziba, hvis din læge vurderer, at dine fordele ved behandlingen opvejer risiciene for fosteret. </p>
<p>Sig det til lægen, hvis du ammer. Undgå at amme under behandling med Qarziba og i 6 måneder efter 
den sidste dosis. Det vides ikke, om lægemidlet kan udskilles i mælken. </p>
<p>Trafik- og arbejdssikkerhed </p>
<p>Qarziba har adskillige bivirkninger, der kan påvirke dine evner til at køre bil og betjene maskiner. Du 
må ikke udføre disse aktiviteter, hvis du føler, at din evne til at koncentrere dig og din reaktionsevne er 
påvirket. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take qarziba"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take qarziba"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>En læge med erfaring i brug af lægemidler til behandling af kræft vil overvåge din behandling. Du vil 
få lægemidlet af en læge eller sygeplejerske, mens du befinder dig på hospitalet. Det vil blive sprøjtet 
direkte ind i din blodåre (intravenøs infusion), normalt ved anvendelse af specielle slanger (katetre) og 
en pumpe. Du vil løbende blive kontrolleret for infusionsrelaterede bivirkninger under og efter 
infusionen. </p>
<p>Du vil få Qarziba i 5 behandlingsserier på hver 35 dage, og infusionen vil blive givet i 5 eller 10 dage i 
begyndelsen af hver behandlingsserie. Den anbefalede dosis er 100 mg dinutuximab beta pr. 
kvadratmeter legemsoverfladeareal i hver behandlingsserie. Lægen vil beregne dit 
legemsoverfladeareal ud fra din højde og vægt. </p>
<p>Hvis din læge finder, at samtidig behandling med interleukin-2 er gavnlig, vil det blive givet som 
subkutan injektion 2 gange i hver serie, hver gang i 5 på hinanden følgende dage (før og under 
behandlingen med Qarziba). </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som alle andre lægemidler give bivirkninger, men ikke alle får bivirkninger. </p>
<p>Tal omgående med din læge eller sygeplejerske, hvis du bemærker noget af følgende: 
Meget almindelig (forekommer hos mere end 1 ud af 10 behandlede): </p>
<ul>
<li>
<p>hurtig opsvulmning af arme, ben og andre kropsdele, hurtigt blodtryksfald, svimmelhed og 
åndedrætsbesvær (kapillærlækage-syndrom) </p>
</li>
<li>
<p>smerter i mave, hals, bryst, ansigt, hænder, fødder, ben, arme, ryg, nakke, led eller muskler </p>
</li>
<li>
<p>allergiske reaktioner og cytokinfrigivelsessyndrom med symptomer såsom opsvulmning af 
ansigt eller hals, åndedrætsbesvær, svimmelhed, nældefeber, hurtige hjerteslag (puls) eller 
hjertebanken, lavt blodtryk, udslæt, feber eller kvalme. </p>
</li>
</ul>
<p>Andre bivirkninger og deres hyppighed er: </p>
<p>Meget almindelig (forekommer hos flere end 1 ud af 10 behandlede): </p>
<ul>
<li>
<p>feber, kuldegysninger </p>
</li>
<li>
<p>opkastning, diarré, forstoppelse </p>
</li>
<li>
<p>betændelse i mundhulen og på læber (stomatitis) </p>
</li>
<li>
<p>hoste </p>
</li>
<li>
<p>kløe, hududslæt </p>
</li>
<li>
<p>lavt blodtryk (svimmelhed), hurtigere hjerteslag (puls) </p>
</li>
<li>
<p>iltmangel </p>
</li>
<li>
<p>hævelse (i ansigt, læber, rundt om øjnene, i benene) </p>
</li>
<li>
<p>vægtstigning </p>
</li>
<li>
<p>infektion, specielt infektion ved kateteret, der bruges i forbindelse med indgivelse af lægemidlet </p>
</li>
<li>
<p>hovedpine </p>
</li>
<li>
<p>større pupiller eller unormale pupilreaktioner </p>
</li>
<li>
<p>unormale blod- eller urinprøver (blodceller og andre bestanddele i blodet, leverfunktion, 
nyrefunktion) </p>
</li>
</ul>
<p>Almindelig (forekommer hos op til 1 ud af 10 behandlede): </p>
<ul>
<li>
<p>livstruende infektion (blodforgiftning - sepsis) </p>
</li>
<li>
<p>epileptiske anfald </p>
</li>
<li>
<p>ophidselse, nervøsitet </p>
</li>
<li>
<p>nerveforstyrrelser i arme og/eller ben (med unormale fornemmelser eller svaghed), svimmelhed, 
rysten, muskelkramper </p>
</li>
<li>
<p>lammelse af øjenmuskler, sløret syn, lysfølsomhed, opsvulmning af nethinden </p>
</li>
<li>
<p>højt blodtryk </p>
</li>
<li>
<p>hjertesvigt, væske rundt om hjertet </p>
</li>
<li>
<p>svigt af åndedrættet, væske i lungerne </p>
</li>
<li>
<p>pludselig blokering af luftvejene (bronkospasme, larynxspasme), hurtig vejrtrækning </p>
</li>
<li>
<p>nedsat appetit, kvalme, udspiling af maven, ophobning af væske i bughulen </p>
</li>
<li>
<p>reaktioner på injektionsstedet, hudproblemer såsom rødme, tør hud, eksem, overdreven 
svedproduktion, unormal reaktion på lys </p>
</li>
<li>
<p>manglende evne til at lade vandet eller lader en mindre mængde urin </p>
</li>
<li>
<p>vægttab, væsketab (dehydrering) </p>
</li>
</ul>
<p>Ikke almindelig (forekommer hos op til 1 ud af 100 behandlede): </p>
<ul>
<li>
<p>Shock pga. nedsat væskemængde i kroppen </p>
</li>
<li>
<p>dannelse af blodpropper i de små blodkar (dissemineret intravaskulær koagulation) </p>
</li>
<li>
<p>en type allergi (serumsygdom) med feber, udslæt, betændelse i led </p>
</li>
<li>
<p>en forstyrrelse i hjernen karakteriseret ved hovedpine, forvirring, kramper og synstab (posteriort 
reversibelt encefalopati-syndrom) </p>
</li>
<li>
<p>betændelse i tarmen, leverskade </p>
</li>
<li>
<p>nyresvigt </p>
</li>
<li>
<p>en tilstand, hvor nogle af de små blodårer i leveren er stoppede (veno-okklusiv sygdom) </p>
</li>
</ul>
<p>Indberetning af bivirkninger 
Hvis du oplever bivirkninger, bør du tale med din læge eller sygeplejerske. Dette gælder også mulige 
bivirkninger, som ikke er medtaget i denne indlægsseddel. Du eller dine pårørende kan også indberette 
bivirkninger direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem anført i Appendiks 
V. Ved at indrapportere bivirkninger kan du hjælpe med at fremskaffe mere information om 
sikkerheden af dette lægemiddel. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store qarziba"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store qarziba"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar lægemidlet utilgængeligt for børn. </p>
<p>Brug ikke dette lægemiddel efter den udløbsdato, der står på etiketten og på kartonen efter EXP. 
Udløbsdatoen er den sidste dag i den nævnte måned. </p>
<p>Opbevares i køleskab (2 °C til 8 °C). Opbevar hætteglasset i den ydre karton for at beskytte det mod 
lys. </p>
<p>Efter åbning bør Qarziba anvendes med det samme. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Qarziba indeholder: </p>
<ul>
<li>
<p>Aktivt stof: dinutuximab beta. 
1 ml koncentrat indeholder 4,5 mg dinutuximab beta. Et hætteglas indeholder 20 mg 
dinutuximab beta i 4,5 ml. </p>
</li>
<li>
<p>Øvrige indholdsstoffer: histidin, saccharose, polysorbat 20, vand til injektionsvæsker, saltsyre 
(til pH-regulering). </p>
</li>
</ul>
<p>Udseende og pakningsstørrelser </p>
<p>Qarziba er en farveløs til let gullig væske, der leveres i et klart hætteglas med gummiprop og 
aluminiumsforsegling. 
Hver æske indeholder 1 hætteglas. </p>
<ul>
<li>
<p>Indehaver af markedsføringstilladelsen 
Recordati Netherlands B.V. 
Beechavenue 54, 
1119PW Schiphol-Rijk 
Holland </p>
</li>
<li>
<p>Fremstiller 
Millmount Healthcare Ltd 
Block 7, City North Business Campus 
Stamullen, Co. Meath 
K32 YDIrland </p>
</li>
</ul>
<p>Patheon Italia S.P.A. 
Via Morolense, 
5 - 03013 Ferentino 
Italien </p>
<p>Denne indlægsseddel blev senest ændret {MM/ÅÅÅÅ}. </p>
<p>Andre informationskilder </p>
<p>Du kan finde yderligere oplysninger om dette lægemiddel på Det Europæiske Lægemiddelagenturs 
hjemmeside: http://www.ema.europa.eu. Der er også links til andre websteder om sjældne sygdomme 
og om, hvordan de behandles. </p>
<hr />
<p>Nedenstående oplysninger er kun til sundhedspersoner: </p>
<p>Qarziba er begrænset til brug på hospitaler og må kun administreres under supervision af en læge med 
erfaring inden for onkologisk behandling. Det skal administreres af sundhedspersonale med erfaring i 
håndtering af alvorlige allergiske reaktioner, heriblandt anafylaksi, i omgivelser, hvor fuldt 
genoplivningsudstyr er umiddelbart tilgængeligt. </p>
<p>Dosering 
Behandling med Qarziba består af 5 på hinanden følgende behandlingsserier, hvor hver serie varer 
35 dage. Den individuelle dosis bestemmes ud fra legemsoverfladeareal og skal samlet være på mg/m2 pr. serie. </p>
<p>Der findes to doseringsmetoder: </p>
<ul>
<li>
<p>Kontinuerlig infusion over de første 10 dage i hver behandlingsserie (samlet 240 timer) med en 
daglig dosis på 10 mg/m2 </p>
</li>
<li>
<p>eller fem daglige infusioner med 20 mg/m2 administreret over 8 timer, på de første 5 dage af 
hver behandlingsserie. </p>
</li>
</ul>
<p>Hvis IL-2 kombineres med dinutuximab beta, skal IL-2 administreres som subkutan injektion 5 på 
hinanden følgende dage to gange i hver behandlingsserie. Den første 5-dages-periode skal starte 
7 dage før den første dinutuximab beta-infusion. Den anden 5-dages-periode med IL-2 skal starte 
samtidig med dinutuximab beta-infusionen (dag 1 til 5 i hver serie). IL-2 administreres som 
6×106 IE/m2/dag, resulterende i en samlet dosis på 60×106 IE/m2/serie. </p>
<p>Fremstilling af infusionsvæske 
Infusionsvæsken skal fremstilles under aseptiske forhold. Infusionsvæsken må ikke udsættes for 
direkte sollys eller varme. </p>
<p>Den patientspecifikke daglige dosis af Qarziba beregnes på grundlag af legemsoverfladearealet (se 
pkt. 4.2). 
Qarziba skal fortyndes aseptisk til den patientspecifikke koncentration/dosis med 9 mg/ml (0,9 %) 
natriumchloridinfusionsvæske indeholdende 1 % humant albumin (f.eks. 5 ml humant albumin 20 % 
til 100 ml natriumchloridinfusionsvæske). </p>
<ul>
<li>
<p>Ved kontinuerlig infusion kan infusionsvæsken fremstilles hver dag eller i en mængde, der er 
tilstrækkelig til op til 5 dages kontinuerlig infusion. Den daglig dosis er 10 mg/m2. Det daglige 
infusionsvolumen (i en behandlingsserie på 10 på hinanden følgende dage) er 48 ml eller 240 ml 
til dosering i 5 dage. Det anbefales at fremstille 50 ml infusionsvæske i en 50 ml sprøjte eller 
250 ml i en infusionspose, der er egnet til den anvendte infusionspumpe, dvs. med en overfyldning 
på 2 ml (sprøjte) eller 10 ml (infusionspose) for at modregne dødvolumenet i infusionssystemet. </p>
</li>
<li>
<p>Ved gentagne daglige 8-timers infusioner er den daglige dosis 20 mg/m2, og den beregnede dosis 
skal fortyndes med 100 ml 9 mg/ml (0,9 %) natriumchloridinfusionsvæske indeholdende 1 % 
humant albumin. </p>
</li>
</ul>
<p>Administration af infusionen 
Infusionsvæsken skal administreres via et perifert eller centralt venekateter. Andre samtidigt 
administrerede intravenøse lægemidler skal indgives gennem en separat infusionsslange. Inden 
administration skal beholderen inspiceres visuelt for partikler. Det anbefales, at et in-line 0,mikrometer filter anvendes under infusionen. </p>
<p>Ved kontinuerlig infusion kan infusionsapparatur egnet til infusion ved en hastighed på 2 ml pr. time 
benyttes, f.eks. infusionspumpe/infusionsapparatur til sprøjte og elektronisk ambulant infusionspumpe. 
Bemærk at elastomer-pumper ikke er egnede til brug sammen med in-line-filtre. </p>
<p>Opbevaring af fortyndet koncentrat (infusionsvæske) 
Der er vist kemisk og fysisk i-brug-stabilitet i op til 48 timer ved 25 °C (50 ml sprøjte) og i op til 7 
dage ved 37 ºC (250 ml infusionspose) efter kumulativ opbevaring i køleskab (2 °C - 8 °C) i 72 timer 
(se pkt. 6.6). </p>
<p>Ud fra en mikrobiologisk synsvinkel skal præparatet anvendes straks. Hvis præparatet ikke anvendes 
straks, er opbevaringstider under brug og forhold før brug brugerens ansvar og må normalt ikke være 
længere end 24 timer ved temperaturer fra 2 til 8 ºC, medmindre fortynding har fundet sted under 
kontrollerede og validerede aseptiske forhold. </p>
<p>Bortskaffelse 
Ikke anvendt lægemiddel samt affald heraf skal bortskaffes i henhold til lokale retningslinjer. </p>         </div>"""      





                    
Instance: bundlepackageleaflet-en-e8b67f07b418969c3e83d3aef06331ab
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for qarziba Package Leaflet for language en"
Description: "ePI document Bundle for qarziba Package Leaflet for language en"
Usage: #example




* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-e8b67f07b418969c3e83d3aef06331ab"
* entry[0].resource = composition-en-e8b67f07b418969c3e83d3aef06331ab

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mpe8b67f07b418969c3e83d3aef06331ab"
* entry[=].resource = mpe8b67f07b418969c3e83d3aef06331ab
                            
                    
Instance: bundlepackageleaflet-da-e8b67f07b418969c3e83d3aef06331ab
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for qarziba Package Leaflet for language da"
Description: "ePI document Bundle for qarziba Package Leaflet for language da"
Usage: #example




* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-e8b67f07b418969c3e83d3aef06331ab"
* entry[0].resource = composition-da-e8b67f07b418969c3e83d3aef06331ab

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mpe8b67f07b418969c3e83d3aef06331ab"
* entry[=].resource = mpe8b67f07b418969c3e83d3aef06331ab
                            
                    



Instance: mpe8b67f07b418969c3e83d3aef06331ab
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product qarziba"
Description: "qarziba"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/17/1191/001"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"


* indication = "Qarziba is indicated for the treatment of high-risk neuroblastoma in patients aged 12 months and"


* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"


* name
  * productName = "qarziba"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#DK "DK"
    * jurisdiction = urn:iso:std:iso:3166#DK "DK"
    * language = urn:ietf:bcp:47#en  "en"




RuleSet: e8b67f07b418969c3e83d3aef06331abListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "qarziba"

* status = #current
* mode = #working

* title = "List of all ePIs associated with qarziba"

* subject = Reference(mpc4c16a48ac49597099fd0a00a176f2b9)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#qarziba "qarziba"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-e8b67f07b418969c3e83d3aef06331ab) // qarziba en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-e8b67f07b418969c3e83d3aef06331ab) // qarziba da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-e8b67f07b418969c3e83d3aef06331ab
InstanceOf: List

* insert e8b67f07b418969c3e83d3aef06331abListRuleset
    